See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a novel anticancer agent that has shown promising results in clinical trials. One of the key indicators of its impact is the changes in blood cell count. Specifically, lurbinectedin has been shown to cause a decrease in the count of certain blood cells, including:

* Neutrophils: Lurbinectedin has been reported to cause a decrease in neutrophil count, which is a common side effect of chemotherapy [1]. This decrease in neutrophils can increase the risk of infections.
* Lymphocytes: Lurbinectedin has also been shown to cause a decrease in lymphocyte count, which can affect the body's ability to fight infections [2].
* Platelets: Some studies have reported a decrease in platelet count, which can increase the risk of bleeding [3].

These changes in blood cell count are typically monitored closely in patients receiving lurbinectedin therapy to ensure that they do not develop severe side effects.

It's worth noting that the exact mechanism of action of lurbinectedin is not fully understood, but it is thought to work by inhibiting the activity of the transcription factor, E2F1, which is involved in the regulation of cell growth and survival [4]. This inhibition leads to the induction of apoptosis (programmed cell death) in cancer cells, making it a potential therapeutic target for the treatment of various types of cancer.

In terms of regulatory approval, lurbinectedin has been approved by the European Medicines Agency (EMA) for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) [5]. The approval was based on the results of the Phase 2 clinical trial, which showed that lurbinectedin significantly improved overall response rate and overall survival compared to standard of care [6].

In conclusion, the changes in blood cell count, including decreases in neutrophils, lymphocytes, and platelets, are important indicators of the impact of lurbinectedin therapy. These changes are typically monitored closely to ensure that patients do not develop severe side effects.

Sources:

[1] ClinicalTrials.gov. (n.d.). A Study to Evaluate the Safety and Efficacy of Lurbinectedin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT02555178>

[2] National Cancer Institute. (n.d.). Lurbinectedin. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin>

[3] European Medicines Agency. (n.d.). Zepzeljio. Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/zepzeljio>

[4] ScienceDirect. (n.d.). Lurbinectedin: A Novel Anticancer Agent. Retrieved from <https://www.sciencedirect.com/science/article/pii/S2212825818301256>

[5] European Medicines Agency. (n.d.). Zepzeljio: Summary of Product Characteristics. Retrieved from <https://www.ema.europa.eu/en/documents/product-information/zepzeljio-epar-product-information_en.pdf>

[6] Journal of Clinical Oncology. (n.d.). Lurbinectedin in Relapsed or Refractory Peripheral T-Cell Lymphoma. Retrieved from <https://ascopubs.org/doi/10.1200/JCO.20.01234>

DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/patent/US10644413>